Webinar: InVitria + Evonik

Register Now

Why Attend This Webinar?

• Understand how animal component-free rHSA can reduce variability and support more defined cell therapy manufacturing workflows.
• See how rHSA performs in iPSC, T cell, and MSC cryopreservation models, including post-thaw outcomes beyond viability.
• Learn how recombinant albumin compares with plasma-derived albumin in purity, consistency, and supply security.
• Get practical guidance on evaluating rHSA for GMP workflows, including formulation fit, qualification, comparability, and closed-system integration.

Featured Products

The session features Evonik’s CreaCyte^® rHSA for biomanufacturing, powered by Optibumin^® 25, InVitria’s ready-to-use 25% liquid recombinant albumin designed for biomanufacturing and closed-system workflows.

Meet the Speakers

Cléa Michel

Global Director Product Management, Biopharma Solutions | Evonik Health Care

Michel leads Evonik’s portfolio of ingredients and technologies for biopharmaceutical manufacturing, from transient protein expression and upstream media optimization to downstream purification and drug product formulation. She draws on a background in biochemistry and biotechnology to help biopharma companies improve process performance.

Dr. Mark Stathos

Director, Cell Biology | InVitria

Dr. Stathos leads InVitria’s Cell Biology lab, producing application notes and publications on how InVitria products perform in industrially relevant applications such as cell and gene therapy manufacturing. He has more than a decade of hands-on cell culture experience and holds a PhD in Bioengineering from Georgia Tech.

Jake Hanks

Director, Business Development | InVitria

Hanks supports InVitria’s key accounts, building strategic partnerships that guide customers through evaluation, qualification, regulatory approval, and scale-up. He holds a BS and an MBA from the University of Tulsa.